Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants

I Badagnani, RA Castro, TR Taylor, CM Brett… - … of Pharmacology and …, 2006 - ASPET
Methotrexate (MTX) is used in patients with malignant and autoimmune diseases. This drug
is primarily excreted unchanged in the urine, and its net excretion occurs via active secretory …

Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney

LM Mangravite, I Badagnani, KM Giacomini - European journal of …, 2003 - Elsevier
Systemic disposition of nucleosides and nucleoside analogs is dependent on renal
handling of these compounds. There are five known, functionally characterized nucleoside …

SLC19A1 pharmacogenomics summary

SW Yee, L Gong, I Badagnani… - Pharmacogenetics …, 2010 - journals.lww.com
Folate is a crucial nutrient that supports the important physiological functions such as DNA
synthesis, cell division and substrate methylation. Low folate level caused by suboptimal …

Discovery and characterization of novel nonsubstrate and substrate NAMPT inhibitors

…, PL Richardson, SM McLoughlin, I Badagnani… - Molecular cancer …, 2017 - AACR
Cancer cells are highly reliant on NAD + -dependent processes, including glucose
metabolism, calcium signaling, DNA repair, and regulation of gene expression. Nicotinamide …

Nonclinical efficacy and safety of CX-2029, an Anti-CD71 probody–drug conjugate

…, O Vasiljeva, Y Li, T Henriques, I Badagnani… - Molecular Cancer …, 2022 - AACR
Probody therapeutics (Pb-Txs) are conditionally activated antibody–drug conjugates (ADCs)
designed to remain inactive until proteolytically activated in the tumor microenvironment, …

Functional genomics of membrane transporters in human populations

…, EH Hurowitz, MK Leabman, I Badagnani… - Genome …, 2006 - genome.cshlp.org
Although considerable progress has been made toward characterizing human DNA sequence
variation, there remains a deficiency in information on human phenotypic variation at the …

[HTML][HTML] Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2

RP Owen, I Badagnani, KM Giacomini - Journal of biological chemistry, 2006 - ASBMB
Members of the concentrative nucleoside transporter (CNT) family (SLC28) mediate the
transport of naturally-occurring nucleosides, and nucleoside analog drugs across the plasma …

SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT)

…, PL Richardson, VL Marin, I Badagnani… - Bioorganic & medicinal …, 2017 - Elsevier
Herein we disclose SAR studies that led to a series of isoindoline ureas which we recently
reported were first-in-class, non-substrate nicotinamide phosphoribosyltransferase (NAMPT) …

Gut-selective design of orally administered izencitinib (TD-1473) limits systemic exposure and effects of janus kinase inhibition in nonclinical species

RN Hardwick, P Brassil, I Badagnani… - Toxicological …, 2022 - academic.oup.com
Izencitinib (TD-1473), an oral, gut-selective pan-Janus kinase (JAK) inhibitor under investigation
for treatment of inflammatory bowel diseases, was designed for optimal efficacy in the …

The metabolic fate of izencitinib, a gut-selective pan-JAK inhibitor, in humans. Identification of unusual fecal metabolites and implications for MIST evaluation

S Yeola, I Badagnani, X Huang, NL Segraves… - Medicinal Chemistry …, 2023 - Springer
Izencitinib is a novel, orally administered pan-JAK inhibitor designed as a gut-selective
therapy that was under development for the treatment of inflammatory bowel disease. The …